A PHASE 3 RANDOMIZED, DOUBLE BLIND, DOUBLE- DUMMY, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-CENTER STUDY INVESTIGATING THE EFFICACY AND SAFETY OF PF-04965842 AND DUPILUMAB IN COMPARISON WITH PLACEBO IN ADULT SUBJECTS ON BACKGROUND TOPICAL THERAPY, WITH MODERATE TO SEVERE ATOPIC DERMATITIS
Phase of Trial: Phase III
Latest Information Update: 15 Feb 2019
At a glance
- Drugs Abrocitinib (Primary) ; Dupilumab
- Indications Atopic dermatitis
- Focus Registrational; Therapeutic Use
- Acronyms JADE Compare
- Sponsors Pfizer
- 03 Dec 2018 Planned End Date changed from 1 Feb 2020 to 2 Feb 2020.
- 03 Dec 2018 Planned primary completion date changed from 1 Feb 2020 to 2 Feb 2020.
- 06 Nov 2018 Status changed from not yet recruiting to recruiting.